SASaúl Astray-Gómez

Saúl Astray-Gómez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Saúl Astray-Gómez has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Current Role of Blue Laser in Otologic Surgery: A Narrative Review

    by Saúl Astray-Gómez, Alexandra Cortés-Arciniegas, Abel Guzmán-Calvete, Carlos De Paula-Vernetta

    Blue laser technology, specifically the 445-450 nm wavelength blue diode laser, represents an emerging innovation in otologic surgery with unique photoangiolytic and hemostatic properties. This narrative review discusses evidence from otologic studies directly addressing the 445-450 nm blue diode laser to evaluate the clinical applications, outcomes, and safety profile of blue laser systems in ear surgery. The technology hasbeen explored in stapedotomy procedures for otosclerosis, middle ear paraganglioma excision, and cholesteatoma surgery. Preliminary and still limited clinical data suggest audiological outcomes broadly comparable to traditional carbon dioxide laser systems, with a proposed advantage in hemostasis and thermal. Direct otologic evidence remains limited to a small number of case series and retrospective comparisons, with most publications emerging between 2018 and 2025. This review identifies blue laser technology as a promising adjunct to the otologic surgeon’s armamentarium, warranting larger randomized controlled trials to establish definitive clinical guidelines and long-term safety profiles.

  • Velopharyngeal Incompetence After Unilateral Botulinum Toxin Injection to the Lateral Pterygoid Muscle for Temporomandibular Joint Disorder

    by Saúl Astray-Gómez, Santiago Almanzo, Inés Tortajada-Torralba, Alexandra Cortés-Arciniegas, Diego Collado-Martín, Miguel Armengot-Carceller

  • Solitary Fibrous Tumor of the Sinonasal Cavity: Case Report and Literature Review

    by Santiago Almanzo, Inés Tortajada-Torralba, Alexandra Cortés-Arciniegas, Saúl Astray-Gómez, Alfonso García-Piñero, Miguel Armengot-Carceller1

    Solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms, most commonly arising in the pleura, but occasionally presenting in extrapleural sites such as the sinonasal tract. Sinonasal SFTs account for less than 6% of head and neck SFTs and often mimic more common nasal pathologies, making diagnosis challenging. The case of a 59-year-old woman with progressive left nasal obstruction, epistaxis, facial paresthesia, and anosmiais reported. Imaging revealed a hypervascular mass (44 Å~ 18 Å~ 43 mm) occupying the left nasal cavity and extending into the adjacent sinuses. Preoperative embolization of the feeding vessels was performed to reduce intraoperative bleeding risk. The tumor was completely resected via an endoscopic approach. Histopathological examination confirmed an SFT with clear margins. Immunohistochemistry showed cluster of differentiation 34(CD34) and signal transducer and activator of transcription 6(STAT6) positivity, along with a low Ki-67 index, indicating low metastatic potential. The postoperative course was uneventful, and the patient remains disease-free at follow-up. Due to their rarity and nonspecific clinical presentation, sinonasal SFTs require a high index of suspicion. Immunohistochemical analysis is essential for definitive diagnosis. Preoperative embolization can be a valuable adjunct in managing vascular lesions. Complete surgical excision is the treatment of choice, and long-term surveillance is recommended to detect potential recurrence. Cite this article as: Almanzo S, Torralba IT, Arciniegas AC, et al. Solitary fibrous tumor of the sinonasal cavity: case report and literature review. B-ENT. 2026;21(4):183-186.

  • Eslicarbazepine as a Treatment for Vestibular Paroxysmia: Preliminary Results

    by Saúl Astray-Gómez, Ana Belén Castilla-Jiménez, Vanesa Pérez-Guillén

    Objective: To assess the potential of eslicarbazepine as an effective and tolerable treatment for vestibular paroxysmia compared to standard drugs. Patients: A cohort of five patients fulfilling criteria of probable or definite vestibular paroxysmia were included in the study. Intervention: Patients were treated with eslicarbazepine in daily regime with an initial dose of 400 mg. Main Outcome Measure: Reduction in number of crises of vestibular paroxysmia per week was measured according to patients’ self-report, to evaluate clinical efficacy. Results: Mean treatment period was 10.6 months. Mean follow-up period was 21 months. Four of the five patients treated with eslicarbazepine achieved a total response with one of the five patients having a partial response with a mean reduction of 70% in the number of crises. The response to the withdrawal of the drug was highly variable in each patient. The most common adverse effects identified in the cohort were nausea, vomiting, and mild biochemical abnormalities. Two of the five patients experienced stochastic effects, which motivated drug removal. Conclusion: Eslicarbazepine shows good preliminary results achieving symptomatic relief in patients diagnosed with vestibular paroxysmia. Its enhanced safety profile with less adverse effects and drug interactions with respect to standard therapies could facilitate therapeutical adherence without detriment of its efficacy.

  • Aberrant intratympanic internal carotid artery

    by Saúl Astray-Gómez, Celia Montón-Gómez, Carlos de Paula-Vernetta

  • Congenital Desmoid Tumor of the Larynx: A Therapeutic Challenge

    by Saúl Astray Gómez, Santiago Almanzo, Adrián Hernández Moya, Agustín Alamar Velázquez, Miguel Armengot Carceller

    Desmoid tumors affecting vital structures can be life-threatening despite their non-malignant behavior. The lack of standardized treatment poses a therapeutic challenge, particularly regarding the sequelae in pediatric patients. A one-month-old male patient presented with respiratory distress and stridor. Endoscopic exploration and computed tomography revealed a laryngeal tumor, which was confirmed as a desmoid tumor via biopsy. Systemic chemotherapy in combination with imatinib was initiated, leading to stabilization of the tumor size. A surgical approach for desmoid tumors may be unsuitable for pediatric patients due to excessive morbidity. In such cases, targeted therapies like tyrosine kinase inhibitors can effectively control the disease.